AbbVie Inc. Stock
€153.08
Your prediction
Description AbbVie
AbbVie (ABBV) is a publicly listed pharmaceuticals company headquartered in North Chicago, Illinois, United States. It was established in 2013 as a spinoff from Abbott Laboratories, and currently operates in more than 175 countries worldwide. The company has over 47,000 employees and specializes in research, development, and the commercialization of advanced therapies for a variety of diseases, including immunology, oncology, neuroscience, and virology.
ABBV's flagship product is Humira, which is used to treat a range of autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is one of the best-selling prescription drugs globally, generating over $19 billion in 2019.
In addition to Humira, AbbVie also has several other leading drugs in its product portfolio, including Imbruvica, which is used to treat B-cell malignancies like leukemia and lymphoma, and Skyrizi, which is used to treat psoriasis.
ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV, and it is a constituent of the S 500 index. As of 2021, AbbVie has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of AbbVie
AbbVie's most important competitors in the pharmaceutical industry are:
1. Johnson Johnson (Symbol: JNJ)
2. Pfizer Inc. (Symbol: PFE)
3. Merck Co., Inc. (Symbol: MRK)
4. Roche Holding AG (Symbol: RHHBY)
5. Sanofi S.A. (Symbol: SNY)
These companies are all large multinational pharmaceutical companies with strong development pipelines, extensive product portfolios, and substantial global reach. They compete with AbbVie in areas such as immunology, oncology, virology, and neuroscience. In addition, they all have a significant presence in emerging markets, where they are competing to capture market share and grow their businesses. Competition in the pharmaceutical industry is intense, and these companies are continually striving to develop new and innovative drugs to stay ahead of their rivals.
Suppliers of AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients. The company has a number of important suppliers that help it manufacture the drugs it develops, and ensure the quality and safety of its products. Here are some of the most important suppliers of AbbVie:
1. Raw materials suppliers: AbbVie sources raw materials such as chemical compounds, active pharmaceutical ingredients (APIs), excipients, and packaging materials from a wide range of suppliers around the world. These include large chemical and pharmaceutical companies, as well as smaller suppliers specialized in specific raw materials.
2. Contract manufacturers: AbbVie works with a number of contract manufacturers to produce its drugs on a large scale. These manufacturers operate facilities in the United States, Europe, and Asia, and are selected based on their expertise in specific manufacturing processes and their ability to meet AbbVie's quality standards.
3. Equipment and technology suppliers: AbbVie also relies on a variety of suppliers for equipment and technology used in its manufacturing processes. These include providers of specialized laboratory equipment, automated drug manufacturing systems, and software systems for tracking and documenting production processes.
4. Service providers: AbbVie works with a range of service providers to ensure the quality and safety of its products. These include companies that provide testing and analysis of raw materials and finished products, logistics and transportation services, and certification and compliance services.
Overall, AbbVie's suppliers play a critical role in the company's ability to develop and deliver innovative medicines to patients around the world. The company has established strong relationships with these suppliers to ensure the reliability and consistency of its supply chain, and continues to seek out new partners to support its ongoing research and development efforts.
Financial data and news for AbbVie
sharewise wants to provide you with the best news and tools for AbbVie, so we directly link to the best financial data sources.
Financials
News
3 Magnificent Stocks That Are Passive Income Machines
There are many dividend stocks on the market. Some will eventually cut or suspend their payouts due to company-specific, economic, or broader market issues. Those aren't the kind of dividend stocks
What Is the Dividend Payout for AbbVie Stock?
Many investors hold a stake in AbbVie (NYSE: ABBV) because it offers exposure to the healthcare sector. Industry-based diversification, however, isn't all the pharmaceutical outfit brings to the
Earn $1000 Every Month From These 3 Stocks
When it comes to dividend investing, I am constantly looking for high-quality companies with strong free cash flows that pay safe, reliable, and growing dividends. In today's video, I will show you
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
The healthcare industry is a fantastic place to find passive income. Healthcare is recession-proof, and there's always a need for better technology and new treatments. The industry's top dogs have
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
Dividend stocks can be great assets for you in retirement. They can provide you with some recurring income, and they can be relatively safe places to invest your money into for a while. Not all
3 Reasons to Buy AbbVie Stock on the Dip
It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this was a long time coming, the market reacted as
Better Dividend Stock: AbbVie or Johnson & Johnson?
There are many dividend stocks on the market, but few are as prominent as AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). These companies have raised their payouts for over 50 consecutive
3 Dividend Stocks to Buy and Hold for the Next Decade
Buy, hold, rake in solid income. That sounds like a pretty good investing strategy. You only have to find the right stocks worthy of holding for the long term and that pay attractive dividends.
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
By almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant delivered first-quarter sales and earnings results that topped estimates. The decline in sales of
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Buying the Dip in These 3 Undervalued Dividend Stocks
We have seen a stock pullback here in April, and three of these high-quality dividend paying stocks look quite intriguing. One of those stocks is healthcare company AbbVie (NYSE: ABBV) which I
Is AbbVie a Millionaire Maker?
Big pharma stocks like AbbVie (NYSE: ABBV) usually aren't high on the list that investors look to for opportunities that could make them into millionaires. After all, they aren't typically in the
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions
3 No-Brainer Dividend Stocks to Buy in April
Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like
2 Top Dividend Stocks to Buy Hand Over Fist
Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase after their share prices drop significantly, which can occasionally be a
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
Stocks have been off to a very bullish start in 2024, and investors seem increasingly optimistic about the overall state of the market and the global economy. Now, that's not to say there aren't
Is AbbVie Stock a Buy Now?
Pharmaceutical giant AbbVie (NYSE: ABBV) is undergoing significant changes. Last year, the company lost U.S. patent exclusivity for its biggest cash cow, immunosuppressant Humira, and is now seeing
3 Dividend Stocks That Are No-Brainer Buys Right Now
There are well over 5,000 stocks on the market that pay dividends. It would take you years to analyze each one of them in detail. Fortunately, you don't have to exert such an effort.
Three Fool.com
Is AbbVie Stock a Buy Now?
Pharmaceutical giant AbbVie (NYSE: ABBV) is getting used to life without Humira. Not literally, but the former global top-seller did lose patent exclusivity last year, and sales plummeted as cheaper
3 Magnificent Growth Stocks to Buy Right Now
In a sense, every investor is a growth investor. If you focus on valuation, you want to find bargain stocks that will grow more in the future than in the past. If you're looking for income, you'll
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (NYSE: ABBV) Humira. That's
Why AbbVie Stock Flew Higher on Monday
Still basking in the afterglow of an encouraging quarterly earnings report, AbbVie (NYSE: ABBV) stock saw a healthy 1.5% rise in price across Monday's trading session. What helped was a series of
3 Fabulous Dividend Stocks to Buy in February
Any time is a good time to buy solid dividend stocks. But this month is a special time to do so for one simple reason: There's an extra day for investors to buy stocks because it's a leap year.
AbbVie (ABBV) Q4 2023 Earnings Call Transcript
2 Beaten-Down Stocks to Buy Hand Over Fist This Year
While the market bounced back last year, some stocks failed to keep pace with broader equities. That was the case with pharma giant AbbVie (NYSE: ABBV) and e-commerce specialist Etsy (NASDAQ: ETSY)